Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 2/3 1

Status

Completed 11Recruiting 7Not yet recruiting 4Active not recruiting 4Unknown 3Terminated 2Suspended 1

Sponsor Class

OTHER 6INDUSTRY 1

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Genitourinary 28Gastrointestinal 20Thoracic 17Breast 17Head & Neck 14Other hematologic neoplasm 13Other solid neoplasm 11Gynecologic 9Lymphoid 8Tumor-Agnostic 7Sarcoma 5Dermatologic 4Plasma cell 3CNS 3Other 2Other neoplasm 1Myeloid 1

Conditions

Neoplasms 6Neoplasm Metastasis 1

Interventions

pembrolizumab 26Specimen Handling 17Blood Specimen Collection 17Biopsy 16Magnetic Resonance Spectroscopy 15atezolizumab 11Surveys and Questionnaires 11Bevacizumab 9Radiotherapy 8Radiosurgery 8Nivolumab 8Fluorouracil 8Standard of Care 7Paclitaxel 7Irinotecan 7Gemcitabine 7Cisplatin 7olaparib 6durvalumab 6Palliative Care 6Oxaliplatin 6Leucovorin 6Cyclophosphamide 6Carboplatin 6Capecitabine 6alectinib 5abemaciclib 5Trastuzumab 5Interviews as Topic 5Exercise 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × Standard of Care × Tumor-Agnostic × Clear all
NCT07005102 2026-06-05

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

AbbVie

Phase 2/3 Recruiting
854 enrolled
Tumor-Agnostic

Neoplasms

NCT07324577 2026-05-22

RELAX

Wake Forest University Health Sciences

Phase NA Recruiting
54 enrolled
Tumor-Agnostic

Neoplasms

NCT05733091 2026-04-21

Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors

M.D. Anderson Cancer Center

Recruiting
300 enrolled
Tumor-Agnostic

Neoplasms

NCT05059678 2026-02-19

Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis

M.D. Anderson Cancer Center

Phase NA Recruiting
120 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05427240 2026-01-16

eReach2

Abramson Cancer Center at Penn Medicine

Phase NA Recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

NCT07183527 2025-09-19

CARES

University of Pittsburgh

Phase NA Recruiting
1,750 enrolled
Tumor-Agnostic

Neoplasms

NCT03257969 2025-03-05

DROP-SFPO

Hospices Civils de Lyon

Phase NA Recruiting
248 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡